Skip to main content
Back
BNTX logo

BioNTech SE

Data quality: 100%
BNTX
NASDAQ Healthcare Biotechnology
$88.77
▲ $1.96 (2.26%)
Mkt Cap: 22.31B
Day Range
$87.76 $89.17
52-Week Range
$79.52 $124.00
Volume
612,881
50D / 200D Avg
$105.31 / $104.33
Prev Close
$86.81

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E -20.4 0.2
P/B 1.2 3.0
ROE % -5.7 3.6
Net Margin % -39.6 3.8
Rev Growth 5Y % -38.3 9.9
D/E 0.0 0.2

Analyst Price Target

Hold
$137.38 +54.8%
Low: $113.00 High: $155.00
Forward EPS
-$4.34
Est. Revenue
2.27B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 -$0.07
-$0.09 – -$0.05
 3.69B 3
FY2029 -$2.48
-$3.24 – -$1.90
 2.94B 3
FY2028 -$3.24
-$9.15 – -$0.73
 2.76B 9

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-10 -$0.19 -$0.38 -100.2%
2025-11-03 -$1.12 -$0.14 +87.5%
2025-08-04 -$2.69 -$1.82 +32.3%
2025-05-05 -$2.48 -$1.82 +26.5%
2025-03-10 $0.46 $1.15 +148.7%
2024-11-04 -$1.74 $0.89 +151.1%
2024-08-05 -$2.19 -$3.62 -65.2%
2024-05-06 -$1.34 -$1.42 -5.9%

Dividend History

1 yr streak

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
Jun 02, 2022 Jun 17, 2022 $2.11 1.33%

Key Takeaways

Revenue declined -38.26% annually over 5 years
Debt/Equity of 0.01 — conservative balance sheet
Generating 269.81M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 38.46%
Capital efficient — spends only 6.10% of revenue on capex

Growth

Revenue Growth (5Y)
-38.26%
Revenue (1Y)0.20%
Earnings (1Y)N/A
FCF Growth (3Y)-75.95%

Quality

Return on Equity
-5.65%
ROIC-2.40%
Net Margin-39.59%
Op. Margin-22.63%

Safety

Debt / Equity
0.01
Current Ratio7.54
Interest Coverage-45.74

Valuation

P/E Ratio
-20.44
Forward P/EN/A
P/B Ratio1.16
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.20% Revenue Growth (3Y) -15.04%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -38.26% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.76B Net Income (TTM) -1.09B
ROE -5.65% ROA -4.96%
Gross Margin 77.64% Operating Margin -22.63%
Net Margin -39.59% Free Cash Flow (TTM) 269.81M
ROIC -2.40% FCF Growth (3Y) -75.95%
Safety
Debt / Equity 0.01 Current Ratio 7.54
Interest Coverage -45.74
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years 1 yrs
Valuation
P/E Ratio -20.44 Forward P/E N/A
P/B Ratio 1.16 P/S Ratio 8.09
PEG Ratio -0.29 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA 19.56
Forward P/S 9.85 Fwd Earnings Yield N/A
FCF Yield 1.21%
Market Cap 22.31B Enterprise Value 14.91B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.76B 2.75B 3.82B 17.31B 18.98B
Net Income -1.09B -665.30M 930.30M 9.43B 10.29B
EPS (Diluted) -4.51 -2.77 3.83 37.09 41.21
Gross Profit 2.14B 2.21B 3.22B 14.32B 16.07B
Operating Income -623.87M -1.31B 690.40M 12.64B 15.28B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 21.98B 22.53B 23.01B 23.28B 15.83B
Total Liabilities 2.76B 3.12B 2.76B 3.22B 3.94B
Shareholders' Equity 19.22B 19.41B 20.25B 20.06B 11.89B
Total Debt 267.29M 254.20M 219.10M 212.20M 301.50M
Cash & Equivalents 7.67B 9.76B 11.66B 13.88B 1.69B
Current Assets 16.14B 18.80B 19.53B 21.92B 15.07B
Current Liabilities 2.14B 2.52B 2.07B 2.95B 3.48B